Search results
15 sty 2014 · Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified …
15 sty 2014 · KRAS mutations activate RAS proteins that continuously stimulate the signalling pathways in the absence of upstream stimulation of EGFR (constitutive activation). Consequently, tumours bearing a KRAS mutation are less likely to respond to anti-EGFR drugs .
30 kwi 2021 · The EGFR, KRAS, and BRAF genes showed wild-type sequences at the mutation hot spots in all 13 specimens. Thus, EGFR might serve as a promising diagnostic marker in canine intestinal adenocarcinoma, and further studies would be needed to develop EGFR-targeted anticancer therapies.
We evaluated EGFR expression at protein and mRNA levels in canine intestinal adenocarcinomas using immunohistochemistry (IHC) and RNA in situ hybridization (RNA-ISH). We also investigated the mutation status of EGFR, KRAS, and BRAF to aid the development of anti-EGFR agents for canine intestinal adenocarcinoma.
One of the most common somatic mutations in colon cancer and NSCLC is the presence of activating mutations in the protooncogene KRAS. KRAS is recruited by ligand-bound (active) EGFR to initiate the signaling cascade induced by the RAS/MAPK pathway.
Epidermal growth factor receptors (EGFR) are tyrosine kinases receptors which are overexpressed or mutated in various malignancies including lung cancer. 5 Binding of epidermal growth factor (EGF) to EGFR activates RAS which is then followed by sequential activation of RAF and finally mitogen-activated protein kinase kinase (MEK). 1, 2, 4.
20 lip 2024 · We present a comprehensive ancestry-based prevalence and co-alteration landscape of genomic alterations and immunotherapy-associated biomarkers in patients with KRAS and EGFR -altered...
